A phase i study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrroles

abstract

  • Obatoclax mesylate administered at 14 mg/m(2) IV on days 1 and 3 is safe and well tolerated when given in combination with topotecan 1.25 mg/m(2) IV on days 1-5 of an every 3-week cycle. A phase II trial to assess the efficacy of this combination for patients with relapsed SCLC is currently accruing patients.

publication date

  • November 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2945625

Digital Object Identifier (DOI)

  • 10.1007/s00280-010-1265-5

PubMed ID

  • 20165849

Additional Document Info

start page

  • 1079

end page

  • 85

volume

  • 66

number

  • 6